Fmr LLC Autolus Therapeutics PLC Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Fmr LLC holds 12,295,167 shares of AUTL stock, worth $45.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

12,295,167

Previous 9,016,390 36.36%

Holding current value

$45.9 Million

Previous $57.5 Million 25.62%

% of portfolio

0.0%

Previous 0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$3.33 - $5.68 $10.9 Million - $18.6 Million	3,278,777 Added 36.36%	12,295,167 $42.8 Million
Q1 2024 May 13, 2024	BUY	$5.39 - $7.29 $48.6 Million - $65.7 Million	9,014,165 Added 405131.0%	9,016,390 $57.5 Million
Q3 2023 Nov 13, 2023	BUY	$2.32 - $3.36 $2,533 - $3,669	1,092 Added 96.38%	2,225 $5,000
Q4 2022 Feb 13, 2023	SELL	$1.74 - $3.27 $661,521 - $1.24 Million	-380,185 Reduced 99.7%	1,133 $2,000
Q3 2022 Nov 10, 2022	BUY	$2.04 - $3.76 $2,311 - $4,260	1,133 Added 0.3%	381,318 $816,000
Q2 2022 Aug 12, 2022	SELL	$2.04 - $4.68 $2.57 Million - $5.91 Million	-1,262,100 Reduced 76.85%	380,185 $1.08 Million
Q4 2021 Feb 14, 2022	BUY	$5.1 - $7.0 $715,514 - $982,079	140,297 Added 9.34%	1,642,285 $8.52 Million
Q3 2021 Nov 15, 2021	SELL	$5.32 - $7.37 $3.02 Million - $4.19 Million	-568,500 Reduced 27.46%	1,501,988 $9.84 Million
Q2 2021 Aug 13, 2021	BUY	$4.78 - $7.96 $9.9 Million - $16.5 Million	2,070,488 New	2,070,488 $13.7 Million

Others Institutions Holding AUTL

# of Institutions

115

Shares Held

167M

Call Options Held

34.2K

Put Options Held

19.5K

View Full List

About Autolus Therapeutics plc

Ticker AUTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,909,800
Market Cap $339M
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...

More about AUTL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account